Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Eligibility criteria
Qualifiers
Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution.
Stage I-III Hodgkin lymphoma (part 3)
Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD).
Eligible for HDT/ASCT
Disqualifiers
Received more than 1 prior treatment (combined modality therapy represents 1 treatment) for Hodgkin Lymphoma
Known pregnancy or breast-feeding.
Breast-feeding should be discontinued prior to treatment initiation.
Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and/or principal investigator, makes participation in this study inappropriate.
Trial design
Treatments tested in this trial
- pembrolizumab
- gemcitabine
- vinorelbine
- liposomal doxorubicin
- Stem cell mobilization and collection
Treatment groups
257 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Locations
10City of Hope Cancer Center (Data Collection Only)91010, DuarteCalifornia, United States
Stanford University Medical Center94305-5408, StanfordCalifornia, United States
University of Miami33136, MiamiFlorida, United States
Memorial Sloan Kettering Basking Ridge07920, Basking RidgeNew Jersey, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov